Omeros (NASDAQ:OMER) Issues Earnings Results

Omeros (NASDAQ:OMER) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29, FiscalAI reports. The firm had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million.

Omeros Price Performance

Shares of NASDAQ:OMER traded down $0.16 during midday trading on Friday, hitting $17.19. The company had a trading volume of 3,673,375 shares, compared to its average volume of 2,166,098. The business’s 50-day simple moving average is $10.89 and its 200-day simple moving average is $11.54. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54. Omeros has a twelve month low of $3.94 and a twelve month high of $18.14.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Key Stories Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter earnings of $0.02 per share, substantially ahead of the expected $0.27 loss, while revenue of $28.53 million more than doubled the $12.69 million consensus estimate. The earnings beat was the primary catalyst for the recent advance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management highlighted a strong launch for YARTEMLEA, along with debt reduction and potential share repurchases. Analysts also pointed to reduced C5 competition as a favorable factor for the company’s commercial outlook. OMER Stock Soars After YARTEMLEA Momentum
• Positive Sentiment: H.C. Wainwright maintained its Buy rating and $33 price target, citing YARTEMLEA’s strong launch and a more favorable competitive environment. The target implies substantial potential upside if the commercial momentum continues. Omeros Buy Rating and $33 Price Target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment could add governance and investment expertise, but its near-term financial impact is unclear. Omeros Appoints Joseph Schocken to Board
• Neutral Sentiment: Trading in OMER call options increased sharply, indicating heightened speculative interest and bullish positioning, but options activity alone does not confirm a sustained fundamental move.
• Negative Sentiment: H.C. Wainwright lowered its long-term EPS forecasts to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. Although the firm retained its Buy rating, the revisions signal some caution about the pace of future earnings growth.

Insider Activity

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the sale, the director directly owned 35,067 shares of the company’s stock, valued at $407,127.87. This trade represents a 17.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming acquired a new position in Omeros in the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Omeros in the 4th quarter valued at approximately $33,000. Arax Advisory Partners increased its holdings in shares of Omeros by 56.4% during the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 1,894 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Omeros by 34.6% during the 4th quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 1,938 shares during the last quarter. Finally, Abel Hall LLC purchased a new stake in shares of Omeros during the 4th quarter valued at approximately $176,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.